113 related articles for article (PubMed ID: 2031200)
1. Lonidamine in metastatic breast cancer.
Rosso R; Amoroso D; Gardin G; Miglietta L; Guido T; Pace M; Repetto L; Pronzato P
Semin Oncol; 1991 Apr; 18(2 Suppl 4):62-5. PubMed ID: 2031200
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of lonidamine in metastatic breast cancer.
Pronzato P; Amoroso D; Bertelli G; Conte PF; Cusimano MP; Ciottoli GB; Gulisano M; Lionetto R; Rosso R
Br J Cancer; 1989 Feb; 59(2):251-3. PubMed ID: 2930690
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of lonidamine in patients with metastatic breast cancer: a National Cancer Institute of Canada Clinical Trials Group Study.
Band PR; Maroun J; Pritchard K; Stewart D; Coppin CM; Wilson K; Eisenhauer EA
Cancer Treat Rep; 1986 Nov; 70(11):1305-10. PubMed ID: 3768873
[TBL] [Abstract][Full Text] [Related]
4. Lonidamine: efficacy and safety in clinical trials for the treatment of solid tumors.
Di Cosimo S; Ferretti G; Papaldo P; Carlini P; Fabi A; Cognetti F
Drugs Today (Barc); 2003 Mar; 39(3):157-74. PubMed ID: 12730701
[TBL] [Abstract][Full Text] [Related]
5. Lonidamine in malignant brain tumors.
Schiffer D; Sales S; Soffietti R
Semin Oncol; 1991 Apr; 18(2 Suppl 4):38-41. PubMed ID: 2031197
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of lonidamine in patients with metastatic breast cancer. An Eastern Cooperative Oncology Group study.
Robins HI; Neuberg DS; Benson AB; Pandya KJ; Tormey DC
Invest New Drugs; 1990 Nov; 8(4):397-9. PubMed ID: 2084074
[TBL] [Abstract][Full Text] [Related]
7. The role of lonidamine in the treatment of breast cancer patients.
Rosso R; Gardin G; Pronzato P; Camoriano A; Merlini L; Naso C; Rosso M; Barone C; Nascimben O; Ianniello G
Ann N Y Acad Sci; 1993 Nov; 698():349-56. PubMed ID: 8279774
[No Abstract] [Full Text] [Related]
8. Phase I toxicologic study of Lonidamine in cancer patients.
Band PR; Deschamps M; Besner JG; Leclaire R; Gervais P; De Sanctis A
Oncology; 1984; 41 Suppl 1():56-9. PubMed ID: 6717896
[TBL] [Abstract][Full Text] [Related]
9. Toxicity and clinical tolerance of lonidamine.
Robustelli della Cuna G; Pedrazzoli P
Semin Oncol; 1991 Apr; 18(2 Suppl 4):18-22. PubMed ID: 2031192
[TBL] [Abstract][Full Text] [Related]
10. Fluorouracil, doxorubicin, and cyclophosphamide versus fluorouracil, doxorubicin, and cyclophosphamide plus lonidamine for the treatment of advanced breast cancer: a multicentric randomized clinical study.
Calabresi F; Di Lauro L; Marolla P; Curcio CG; Paoletti G; Calabró A; Giannarelli D; Ballatore P; Foggi CM; Di Palma M
Semin Oncol; 1991 Apr; 18(2 Suppl 4):66-72. PubMed ID: 2031201
[TBL] [Abstract][Full Text] [Related]
11. The combined use of radiation therapy and lonidamine in the treatment of brain metastases.
DeAngelis LM; Currie VE; Kim JH; Krol G; O'Hehir MA; Farag FM; Young CW; Posner JB
J Neurooncol; 1989 Sep; 7(3):241-7. PubMed ID: 2677257
[TBL] [Abstract][Full Text] [Related]
12. A phase II clinical and pharmacokinetic study of Lonidamine in patients with advanced breast cancer.
Mansi JL; de Graeff A; Newell DR; Glaholm J; Button D; Leach MO; Payne G; Smith IE
Br J Cancer; 1991 Sep; 64(3):593-7. PubMed ID: 1911204
[TBL] [Abstract][Full Text] [Related]
13. Lonidamine in high-risk breast cancer patients.
Possinger K; Wagner H; Kovacs S; Flath B; Classen S; Wilmanns W
Semin Oncol; 1991 Apr; 18(2 Suppl 4):58-61. PubMed ID: 2031199
[TBL] [Abstract][Full Text] [Related]
14. Effect of lonidamine on the cytotoxicity of four alkylating agents in vitro.
Rosbe KW; Brann TW; Holden SA; Teicher BA; Frei E
Cancer Chemother Pharmacol; 1989; 25(1):32-6. PubMed ID: 2590999
[TBL] [Abstract][Full Text] [Related]
15. Phase III trial with and without lonidamine in non-small cell lung cancer.
Gatzemeier U; Cavalli F; Häussinger K; Kaukel E; Koschel G; Martinelli G; Neuhauss R; von Pawel J
Semin Oncol; 1991 Apr; 18(2 Suppl 4):42-8. PubMed ID: 1851577
[TBL] [Abstract][Full Text] [Related]
16. The pharmacokinetics of oral lonidamine in breast and lung cancer patients.
Newell DR; Mansi J; Hardy J; Button D; Jenns K; Smith IE; Picollo R; Catanese B
Semin Oncol; 1991 Apr; 18(2 Suppl 4):11-7. PubMed ID: 2031191
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of lonidamine combined with different DNA-damaging agents in the treatment of the MX-1 tumor xenograft.
Pratesi G; De Cesare M; Zunino F
Cancer Chemother Pharmacol; 1996; 38(2):123-8. PubMed ID: 8616901
[TBL] [Abstract][Full Text] [Related]
18. Phase II evaluation of Lonidamine in patients with advanced malignancy.
Evans WK; Shepherd FA; Mullis B
Oncology; 1984; 41 Suppl 1():69-77. PubMed ID: 6717899
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin, epirubicin, and lonidamine combination regimen as first-line chemotherapy for metastatic breast cancer: a pilot study.
Dogliotti L; Danese S; Berruti A; Zola P; Buniva T; Bottini A; Richiardi G; Moro G; Farris A; Baù MG; Porcile G
Cancer Chemother Pharmacol; 1998; 41(4):333-8. PubMed ID: 9488603
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of Lonidamine in cancer patients.
Band PR; Deschamps M; Besner JG; Leclaire R; Gervais P; De Sanctis A
Oncology; 1984; 41 Suppl 1():66-8. PubMed ID: 6717898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
